EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions

Hiba J Mustafa iD, Yair J Blumenfeld, Ramen H Chmait, Jennifer L Taylor-Cousar, Jordana E Hoppe iD, Stacey L Martiniano, Angela Metcalf iD, Scott D Sagel, Edith T Zemanick, Alireza A Shamshirsaz, Sylvia E Szentpetery, Aaron T Trimble iD und 4 weitere

Pregnancy · 2026-07 · 2 (4)

DOI: 10.1002/pmf2.70317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pregnancy, online erschienen am 16.07.2026. Verfasst von Hiba J Mustafa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal-Fetal Medicine The Fetal Center at Indiana University and Riley Children's Health Indianapolis Indiana USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The consequences of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein dysfunction or absence begin during fetal development, with pancreatic, intestinal, hepatobiliary, and reproductive manifestations evident at birth. The advent of CFTR modulator therapies (CFTR modulator)—most notably elexacaftor/tezacaftor/ivacaftor (ETI), approved for children and adults with CF who carry responsive variants, and the recently approved vanzacaftor/tezacaftor/deutivacaftor (VTD), currently indicated for older pediatric and adult populations—has transformed long‐term health outcomes and substantially increased the number of pregnancies among individuals with CF. As maternal use of CFTR modulator during pregnancy has become more common, early observational studies and case series suggest potential fetal benefit for fetuses affected by CF, particularly with respect to inspissated meconium obstructing the terminal ileum, potentially reducing the need for postnatal surgical intervention.

Methods

To synthesize current evidence regarding maternal, fetal, and neonatal outcomes following prenatal CFTR modulator exposure; describe the rationale and early experience with intentional prenatal therapy for affected fetuses; and outline practical counseling and monitoring strategies. Evidence was drawn from clinical pregnancy cohorts, pharmacokinetic studies, case series treating fetal meconium ileus, mechanistic fetal and animal models, and expert consensus documents, including the PRenatal MOdulator Treatment to PrEvent CF ComplicaTions (PROTECT) Workshop summary. Both maternal‐ and fetal‐indication uses of CFTR modulator were evaluated.

Results

Continuation of ETI during pregnancy has been associated with stabilization of maternal pulmonary function and nutritional status and has not been linked to an increased risk of congenital anomalies, preterm delivery, or miscarriage in available observational cohorts. Both ETI and VTD cross the placenta and achieve fetal drug exposure at concentrations expected to be pharmacologically active. Case series in fetuses with CF describe improvement or resolution of prenatal bowel abnormalities indicative of evolving meconium ileus, with suggestive evidence of preservation of exocrine pancreatic function and the male reproductive tract in limited cases. Cataracts have rarely been reported, are typically small and not visually significant, and have not been consistently observed across cohorts. Prenatal exposure may result in falsely negative newborn screening results. However, the optimal timing and duration of prenatal modulator initiation for fetal benefit, fetal pharmacokinetics and pharmacodynamics, and long‐term neurodevelopmental outcomes remain uncertain.

Conclusion

Prenatal CFTR modulator therapy shows promise as the first fetal therapy for CF. While continuation for maternal CF is supported by available evidence (although not label‐approved), fetal‐indication use remains investigational. Robust counseling, interdisciplinary coordination, and structured monitoring are essential, alongside ongoing research to define therapeutic windows, safety, and long‐term outcomes.

Schlagwörter

Stichwörter der Autor:innen

CFTRETITrikaftacystic fibrosisfetal therapymeconium ileusmodulator therapyprenatal therapy

Autor:innen und Institutionen

  • Division of Maternal-Fetal Medicine The Fetal Center at Indiana University and Riley Children's Health Indianapolis Indiana USA.
  • Department of Obstetrics & Gynecology Division of Maternal-Fetal Medicine and Obstetrics School of Medicine Stanford University Stanford California USA.
  • Department of Obstetrics and Gynecology Division of Maternal-Fetal Medicine Keck School of Medicine University of Southern California Los Angeles California USA.
  • Departments of Medicine and Pediatrics National Jewish Health University of Colorado Anschutz Medical Campus Denver Colorado USA.
  • Department of Pediatrics Children's Hospital Colorado University of Colorado Anschutz Medical Campus Aurora Colorado USA.
  • Comprehensive Fetal Care Center at Dell Children's Dell Children's Medical Center Austin Texas USA.

ORCID-Profile: Hiba J Mustafa, Jordana E Hoppe, Angela Metcalf, Aaron T Trimble, Elizabeth B Burgener, Isabelle Sermet-Gaudelus, Michael V Zaretsky

Zitieren

APA

Mustafa, H. J., Blumenfeld, Y. J., Chmait, R. H., Taylor-Cousar, J. L., Hoppe, J. E., Martiniano, S. L., Metcalf, A., Sagel, S. D., Zemanick, E. T., Shamshirsaz, A. A., Szentpetery, S. E., Trimble, A. T., Burgener, E. B., Luna-Paredes, C., Sermet-Gaudelus, I., & Zaretsky, M. V. (2026). Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions. Pregnancy, 2(4). https://doi.org/10.1002/pmf2.70317

Vancouver

Mustafa HJ, Blumenfeld YJ, Chmait RH, Taylor-Cousar JL, Hoppe JE, Martiniano SL, et al. Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions. Pregnancy. 2026;2(4). doi:10.1002/pmf2.70317

BibTeX
@article{Mustafa2026,
  author = {Mustafa, Hiba J and Blumenfeld, Yair J and Chmait, Ramen H and Taylor-Cousar, Jennifer L and Hoppe, Jordana E and Martiniano, Stacey L and Metcalf, Angela and Sagel, Scott D and Zemanick, Edith T and Shamshirsaz, Alireza A and Szentpetery, Sylvia E and Trimble, Aaron T and Burgener, Elizabeth B and Luna-Paredes, Carmen and Sermet-Gaudelus, Isabelle and Zaretsky, Michael V},
  title = {Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions},
  journal = {Pregnancy},
  year = {2026},
  volume = {2},
  number = {4},
  doi = {10.1002/pmf2.70317}
}
Kostenlos starten →